By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces metastatic spread in mouse models of prostate, breast and lung cancer.
[More]
Personal Genome Diagnostics Inc., today announced that it will use its proprietary methodologies and expertise in genomic analysis of defined cancer subtypes to identify novel kinase targets in collaboration with Blueprint Medicines.
[More]
Kinase inhibitors are molecules that block the activity of kinases. Kinases are a specific class of enzymes. They are extremely important in signal transduction processes in the human body meaning that they actually regulate most of the physiological processes that take place in the body.
[More]
The media tittering over Mrs. Colbert Busch's decision to publicly slap the former Republican governor over his extramarital affair obscured the more notable political comment of the night.
[More]
More than 100 cancer specialists call for pharmaceutical companies to lower the prices of these drugs that patients need to live.
[More]
Hagop Kantarjian, M.D., chair and professor in The University of Texas MD Anderson Cancer Center's Department of Leukemia, will be honored for clinical research excellence at the AACR Annual Meeting 2013, April 6-10.
[More]
Professor Alex Matter, Chief Executive Officer of A*STAR's Experimental Therapeutics Centre (ETC), has been awarded the 8th Annual Szent-Gy-rgyi Prize for Progress in Cancer Research by the National Foundation for Cancer Research (NFCR) for his contributions to the development of the first drug specifically targeting a molecular lesion in cancer.
[More]
A Saint Louis University researcher has received a contract worth up to $980,000 to see if two cancer medications have the potential of protecting U.S. troops from biological agents that could be unleashed during an attack.
[More]
The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease.
[More]
Charles L. Sawyers, Chair of Memorial Sloan-Kettering's Human Oncology and Pathogenesis Program (HOPP), was awarded the Breakthrough Prize in Life Sciences today. The award - established by Art Levinson, Sergey Brin, Anne Wojcicki, Mark Zuckerberg, Priscilla Chan, and Yuri Milner - recognizes "excellence in research aimed at curing intractable diseases and extending human life."
[More]
A drug that is currently used for cancer can relieve and slow down the progression of the autoimmune disease multiple sclerosis (MS) in rats, according to a new study published in PLOS ONE.
[More]
The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
[More]
Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms are sensitive - and thus vulnerable - to a novel cancer stem cell-targeting drug currently under development.
[More]
An international team of scientists, led by researchers from Temple University School of Medicine, has found that a source of mounting genomic chaos, or instability, common to chronic myeloid leukemia (CML) may lie in a pool of leukemia stem cells that are immune to treatment with potent targeted anticancer drugs.
[More]
Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia (CML), a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse. These leukemia stem cells are full of genetic errors, loaded with potentially lethal breaks in DNA, and are in a state of constant self-repair.
[More]
Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.
[More]
A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine.
[More]
A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial.
[More]
Physician-researchers at Indiana University School of Medicine have reported the first effective therapy for a class of previously untreatable and potentially life-threatening tumors often found in children.
[More]
Proteins accelerate certain chemical reactions in cells by several orders of magnitude. The molecular mechanism by which the Ras protein accelerates the cleavage of the molecule GTP and thus slows cell growth is described by biophysicists at the Ruhr-Universit-t Bochum led by Prof. Dr. Klaus Gerwert in the Online Early Edition of the journal PNAS.
[More]